Phase 1 Study of the Effect of Icosapent Ethyl on Warfarin Pharmacokinetic and Anticoagulation Parameters
- 146 Downloads
Background and Objective
Icosapent ethyl (IPE) is a high-purity prescription form of eicosapentaenoic acid (EPA) ethyl ester approved to reduce triglyceride levels in patients with severe (≥5.65 mmol/L) hypertriglyceridemia. EPA, the active metabolite of IPE, is mainly metabolized via β-oxidation, and studies suggest that omega-3 fatty acids such as EPA may have antithrombotic effects. The objective of this study was to evaluate the effect of IPE on the pharmacokinetic and anticoagulation pharmacodynamics of warfarin, a substrate of cytochrome P450 2C9-mediated metabolism.
Healthy adults received oral warfarin (25 mg) on day 1, oral IPE (4 g/day) on days 8–35, and co-administration on Day 29. Primary pharmacokinetic end points were area under the concentration-versus-time curve from zero to infinity (AUC0–∞) and maximum plasma concentration (C max) for R- and S-warfarin; pharmacodynamic end points were area under the international normalized ratio (INR) effect-time curve after the warfarin dose (AUCINR) and maximum INR (INRmax).
Twenty-five subjects completed the study. AUC0–∞ and C max ratios of geometric means for both R- and S-warfarin following co-administration of warfarin with versus without IPE were within the 90 % confidence intervals of 0.80–1.25. AUCINR, INRmax, and ratios were also similar.
IPE 4 g/day did not significantly change the single-dose AUC0–∞ or C max of R- and S-warfarin or the anticoagulation pharmacodynamics of warfarin when co-administered as racemic warfarin at 25 mg. Co-administration of these drugs was safe and well tolerated in this study of healthy adult subjects.
KeywordsWarfarin International Normalize Ratio Ezetimibe Racemic Warfarin International Sensitivity Index
This study was designed and sponsored by Amarin Pharma Inc., Bedminster, NJ, USA. Drs. Braeckman and Soni are former employees of Amarin Pharma Inc., Bedminster, NJ, USA, and were employed by Amarin Pharma Inc. during the planning, execution, and manuscript preparation of this study. Medical writing assistance was provided by Beth Daro-Kaftan, PhD, of Peloton Advantage, LLC, Parsippany, NJ, USA, and funded by Amarin Pharma Inc.
- 3.Vascepa [package insert]. Bedminster, NJ: Amarin Pharma Inc.; 2013.Google Scholar
- 4.Bays HE, Ballantyne CM, Kastelein JJ, et al. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial). Am J Cardiol. 2011;108:682–90.PubMedCrossRefGoogle Scholar
- 7.Coumadin [package insert]. Princeton, NJ: Bristol-Myers Squibb; 2011.Google Scholar
- 10.Wachira JK, Larson MK, Harris WS. n-3 Fatty acids affect haemostasis but do not increase the risk of bleeding: clinical observations and mechanistic insights. Br J Nutr. 2014;111:1652–62.Google Scholar
- 17.Guidance for industry. Drug interaction studies—study design, data analysis, and implications for dosing and labeling. U.S. Department of Health and Human Services; Food and Drug Administration. http://www.fda.gov/OHRMS/DOCKETS/98fr/06d-0344-gdl0001.pdf. Accessed 25 March 2014.
- 18.Braeckman RA, Stirtan WG, Soni PN. Pharmacokinetics of eicosapentaenoic acid in plasma and red blood cells after multiple oral dosing with icosapent ethyl in healthy subjects. Clin Pharmacol Drug Devel. 2013 (Epub ahead of print). doi: 10.1002/cpdd.84/abstract.
- 30.Lovaza [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2013.Google Scholar